Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PharmAkea

- PMLiVE

UK financial authority confirms Woodford probe

Biotech investor in cross-hairs

- PMLiVE

Twentyeight-Seven raises another $15m for non-coding RNA drugs

Adds to funds raised from pharma venture units

- PMLiVE

Alector kicks off next wave of biotech IPOs

US biotech raising money again

- PMLiVE

UK biotech booms in 2018, despite Brexit worries

Industry attracted a record-breaking £2.2bn in investment last year

- PMLiVE

Moderna CEO makes case for firm’s lofty valuation

mRNA specialist has to convince investors after stocks slide

- PMLiVE

After December slump, what’s in store for biotech in 2019?

Analysts say 2019 could be a "big year for proceeds if not for deal count"

Navigating the antibiotic resistance crisis

Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Blue Latitude Health

Report: Achieving launch excellence in the challenging healthcare markets of today

Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Blue Latitude Health

- PMLiVE

Moderna files record $500m IPO for RNA pipeline

Could be the largest IPO for a biotech start-up

- PMLiVE

Genetic counsellors: the new healthcare influencers?

Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.

Blue Latitude Health

Mastering the precision medicine opportunity

The rise of precision medicine will transform the pharma business model, challenging the way we commercialise therapies. BLH Senior Consultant and precision medicine expert David Cooney, reveals how you can...

Blue Latitude Health

- PMLiVE

China’s BeiGene raises $903m from Hong Kong IPO

Mammoth debut might have exceeded $1bn but for market jitters

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links